GT Biopharma stock (US36254L1098): First patient dosed in solid tumor trial

GT Biopharma announced on May 14, 2026, that it has dosed the first patient in a Phase 1 trial of GTB-5550, marking the company's expansion into solid tumor treatment with its proprietary natural killer cell engager technology.

GT Biopharma announced the dosing of the first patient in a Phase 1 trial of GTB-5550, a B7-H3-targeted natural killer (NK) cell engager designed for solid tumors, according to GT Biopharma press release as of May 14, 2026. This represents the company's third TriKE therapy to enter clinical trials and signals a strategic expansion beyond its initial hematologic malignancy focus into the broader solid tumor oncology market.

As of: May 14, 2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: GT Biopharma, Inc.
• Sector/industry: Biopharmaceutical – immuno-oncology
• Headquarters/country: United States
• Core markets: Oncology, hematologic malignancies, solid tumors
• Key revenue drivers: Clinical-stage development of TriKE therapies and NK cell engagers
• Home exchange/listing venue: Nasdaq (GTBP)
• Trading currency: USD

GT Biopharma: clinical-stage immuno-oncology developer

GT Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing immuno-oncology therapeutic products based on its proprietary TriKE (Tri-specific Killer Engager) platform technology. The company's approach leverages natural killer cells to target and eliminate cancer cells, representing an alternative mechanism within the broader immuno-oncology landscape dominated by checkpoint inhibitors and CAR-T therapies. For US investors, GT Biopharma trades on Nasdaq under the ticker GTBP and represents exposure to early-stage oncology innovation.

GTB-5550 and the solid tumor expansion

The dosing of the first patient in the GTB-5550 Phase 1 trial marks a significant milestone for the company's pipeline diversification. GTB-5550 is designed to target B7-H3, a tumor-associated antigen expressed on solid tumors, using the company's NK cell engager technology. This expansion into solid tumors broadens the addressable market beyond hematologic malignancies, where the company's earlier TriKE programs have been evaluated. The Phase 1 dose escalation study will evaluate safety, tolerability, and preliminary efficacy in patients with B7-H3-positive solid tumors.

Conclusion

GT Biopharma's advancement of GTB-5550 into clinical trials represents a key development for the company's pipeline and market positioning within immuno-oncology. The transition from hematologic malignancies to solid tumors expands the potential patient population and commercial opportunity. Clinical-stage biotech companies carry inherent development and regulatory risks; investors should monitor trial progress, safety data, and competitive dynamics in the NK cell therapy space.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.